Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 58
Filter
1.
Frontiers of Medicine ; (4): 58-67, 2023.
Article in English | WPRIM | ID: wpr-971626

ABSTRACT

The current organ allocation rules prioritize elderly and urgent patients on the lung transplantation (LT) waiting list. A steady increase in the threshold at which age is taken into consideration for LT has been observed. This retrospective cohort study recruited 166 lung transplant recipients aged ≽ 65 years between January 2016 and October 2020 in the largest LT center in China. In the cohort, subgroups of patients aged 65-70 years (111 recipients, group 65-70) and ≽ 70 years (55 recipients, group ≽ 70) were included. Group D restrictive lung disease was the main indication of a lung transplant in recipients over 65 years. A significantly higher percentage of coronary artery stenosis was observed in the group ≽ 70 (30.9% vs. 14.4% in group 65-70, P = 0.014). ECMO bridging to LT was performed in 5.4% (group 65-70) and 7.3% (group ≽ 70) of patients. Kaplan-Meier estimates showed that recipients with cardiac abnormalities had a significantly increased risk of mortality. After adjusting for potential confounders, cardiac abnormality was shown to be independently associated with the increased risk of post-LT mortality (HR 6.37, P = 0.0060). Our result showed that LT can be performed in candidates with an advanced age and can provide life-extending benefits.


Subject(s)
Aged , Humans , East Asian People , Heart Diseases/etiology , Lung Transplantation/adverse effects , Retrospective Studies
2.
Clin. biomed. res ; 42(1): 1-6, 2022.
Article in English, Portuguese | LILACS | ID: biblio-1381407

ABSTRACT

Introdução: O uso de terapia imunossupressora é de extrema importância no transplante pulmonar, entretanto existem diversas reações adversas (RAMs) associadas ao seu uso. Neste trabalho buscamos descrever a incidência de perda de função renal (FR), diabetes mellitus (DM), hipertensão arterial sistêmica (HAS) e hipercolesterolemia associadas ao uso de ICN na população de transplantados pulmonares do Hospital de Clínicas de Porto Alegre após 1 ano de transplante.Metodologia: Estudo de coorte retrospectivo, conduzido no Hospital de Clínicas de Porto Alegre. Foram incluídos os pacientes transplantados de pulmão no período de 2016 a 2018.Resultados: Após um ano do transplante 56,5% (13/23) tiveram uma perda de FR em comparação ao basal, mas com valores ainda dentro da normalidade e 30,4% (7/23) perderam FR. A diferença de FR antes e após o transplante foi estatisticamente significativa com p < 0,001, no entanto não foi observado diferença entre os ICN (p = 0,499). Entre as variáveis: DM, HAS e Hipercolesterolemia, apenas o desenvolvimento de HAS foi estaticamente significativo quando comparado ao período pré-transplante (p < 0,001).Conclusão: Nossos dados demonstraram importante perda de FR após uso de imunossupressores ICN, corroborando com dados já publicados, no entanto, não foi possível identificar associação com ICN específico, sugerindo que benefícios na intercambialidade de terapias entre os ICN na tentativa de preservação da FR devem ser melhor estudados. Diante da possibilidade de desenvolvimento de RAMs associadas ao uso de imunossupressores, destacamos a importância da inserção do farmacêutico clínico nas equipes de transplante.


Introduction: Immunosuppressive therapy is extremely important in lung transplantation, but there are several adverse drug reactions (ADRs) associated with its use.Objective: To report the incidence of loss of renal function (RF), diabetes mellitus (DM), systemic arterial hypertension (SAH), and hypercholesterolemia associated with the use of calcineurin inhibitors (CNIs) in the population of lung transplant recipients at Hospital de Clínicas de Porto Alegre at 1 year after transplant. Methods: We conducted a retrospective cohort study of patients undergoing a lung transplant at Hospital de Clínicas de Porto Alegre from 2016 to 2018.Results: At 1 year after transplant, 56.5% (13/23) had loss of RF compared with baseline, but the values remained within the normal range, whereas 30.4% (7/23) had complete loss of RF. There was a statistically significant difference in RF before and after transplant (p < 0.001), but not in CNIs (p = 0.499). Among the variables DM, SAH, and hypercholesterolemia, only the development of SAH was statistically significant compared with the pre-transplant period (p < 0.001).Conclusion: Our data demonstrated an important loss of RF after the use of CNI immunosuppressants, which is consistent with published data. However, no association was identified with the type of CNI, suggesting that the benefits of the interchangeability of CNI therapies aimed at preserving RF should be further studied. Given the potential occurrence of ADRs associated with the use of immunosuppressants, we highlight the importance of the presence of a clinical pharmacist in the transplant team.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Immunosuppression Therapy/adverse effects , Lung Transplantation/adverse effects , Calcineurin Inhibitors/adverse effects , Cohort Studies
3.
Rev. bras. cir. cardiovasc ; 36(6): 760-768, Nov.-Dec. 2021. tab, graf
Article in English | LILACS | ID: biblio-1351677

ABSTRACT

Abstract Introduction: The aim of this study was to evaluate the delayed chest closure (DCC) results in patients who underwent lung transplantation. Methods: Sixty patients were evaluated retrospectively. Only bilateral lung transplantations and DCC for oversized lung allograft (OLA) were included in the study. Six patients who underwent single lung transplantation, four patients who underwent lobar transplantation, two patients who underwent retransplantation, and four patients who underwent DCC due to bleeding risk were excluded from the study. Forty-four patients were divided into groups as primary chest closure (PCC) (n=28) and DCC (n=16). Demographics, donor characteristics, and operative features and outcomes of the patients were compared. Results: The mean age was 44.5 years. There was no significant difference between the demographics of the groups (P>0.05). The donor/recipient predicted total lung capacity ratio was significantly higher in the DCC group than in the PCC group (1.06 vs. 0.96, P=0.008). Extubation time (4.3 vs. 3.1 days, P=0.002) and intensive care unit length of stay (7.6 vs. 5.2 days, P=0.016) were significantly higher in the DCC group than in the PCC group. In the DCC group, postoperative wound infection was significantly higher than in the PCC group (18.6% vs. 0%, P=0.19). Median survival was 14 months in all patients and there was no significant difference in survival between the groups (16 vs. 13 months, P=0.300). Conclusion: DCC is a safe and effective method for the management of OLA in lung transplantation.


Subject(s)
Humans , Adult , Lung Transplantation/adverse effects , Lung Transplantation/methods , Turkey , Retrospective Studies , Treatment Outcome , Allografts , Lung
4.
Rev. chil. enferm. respir ; 37(1): 11-16, mar. 2021. tab, ilus
Article in Spanish | LILACS | ID: biblio-1388128

ABSTRACT

El trasplante de pulmón (TP) es una opción para pacientes pediátricos con enfermedades pulmonares terminales. OBJETIVO: Evaluar resultados y sobrevida de pacientes pediátricos trasplantados de pulmón. MÉTODOS: Análisis retrospectivo de registros clínicos de pacientes TP ≤ 15 años de Clínica Las Condes. Se analizaron datos demográficos, tipo de trasplante, función pulmonar basal y post trasplante, complicaciones precoces y tardías y sobrevida. RESULTADOS: Nueve pacientes < 15 años de edad se han trasplantado. La edad promedio fue 12,7 años. La principal indicación fue fibrosis quística (7 pacientes). El IMC promedio fue de 17,6 y todos estaban con oxígeno domiciliario. El 77% utilizó soporte extracorpóreo intraoperatorio. Las principales complicaciones precoces fueron hemorragia y la disfunción primaria de injerto mientras que las tardías fueron principalmente las infecciones y la disfunción crónica de injerto. Cuatro pacientes han fallecido y la sobrevida a dos años fue de 85%. El trasplante les permitió una reinserción escolar y 3 lograron completar estudios universitarios. CONCLUSIÓN: El trasplante pulmonar es una alternativa para niños con enfermedades pulmonares avanzadas mejorando su sobrevida y calidad de vida.


Lung transplantation (TP) is a treatment option in children with terminal lung diseases. OBJECTIVE: To evaluate the results and survival of pediatrics lung transplant patients. METHODS: Retrospective analysis of clinical records of lung transplantation of patients ≤ 15 years from Clínica Las Condes, Santiago, Chile. Demographic data, type of transplant, baseline and post transplant lung function, early and late complications and survival rate were analyzed. RESULTS: Nine patients ≤ 15 years-old were transplanted. The average age at transplant was 12.7 years. The main indication was cystic fibrosis (7 patients). The average BMI was 17.6 and all the patients were with home oxygen therapy. 77% used extracorporeal intraoperative support. Average baseline FEV1 was 25.2% with progressive improvement in FEV1 of 77% in the first year. The main early complications were hemorrhage and primary graft dysfunction, while late complications were infections and chronic graft dysfunction. Four patients have died and the estimated 2 years survival was 85%. They achieved school reinsertion and three managed to complete university studies. CONCLUSION: Lung transplantation is an alternative for children with advanced lung diseases improving their survival and quality of life.


Subject(s)
Humans , Male , Female , Child , Adolescent , Lung Transplantation/statistics & numerical data , Lung Diseases/surgery , Pediatrics , Bronchiolitis Obliterans , Extracorporeal Membrane Oxygenation , Survival Analysis , Chile , Retrospective Studies , Follow-Up Studies , Lung Transplantation/adverse effects , Lung Transplantation/mortality , Treatment Outcome , Postoperative Hemorrhage/etiology , Cystic Fibrosis , Primary Graft Dysfunction/etiology , Hypertension, Pulmonary , Lung Diseases/mortality
6.
Journal of Central South University(Medical Sciences) ; (12): 1172-1176, 2021.
Article in English | WPRIM | ID: wpr-922600

ABSTRACT

Antibody-mediated rejection (AMR) is a rare and serious complication after lung transplantation, with no characteristic of pathological manifestation, no systematic standard treatment, and the poor efficacy and prognosis. We reported a case of early AMR after lung transplantation and the relevant literature has been reviewed. A male patient presented with symptoms of cold 99 days after transplantation and resolved after symptomatic treatment. He admitted to the hospital 14 days later because of a sudden dyspnea and fever. Anti-bacteria, anti-fungi, anti-virus, and anti-pneumocystis carinii treatment were ineffective, and a dose of 1 000 mg methylprednisolone did not work too. The patient's condition deteriorated rapidly and tracheal intubation was done to maintain breathing. Serum panel reactive antibody and donor specific antibody showed postive in humen leukocyte antigen (HLA) II antibody. Pathological examination after transbronchial transplantation lung biopsy showed acute rejection. Clinical AMR was diagnosed combined the donor-specific antibody with the pathological result. The patient was functionally recovered after combined treatment with thymoglobuline, rituximab, plasmapheresis, and immunoglobulin. No chronic lung allograft dysfunction was found after 3 years follow up. We should alert the occurrence of AMR in lung transplantation recipient who admitted to hospital with a sudden dyspnea and fever while showed no effect after common anti-infection and anti-rejection treatment. Transbronchial transplantation lung biopsy and the presence of serum donor-specific antibody are helpful to the diagnosis. The treatment should be preemptive and a comprehensive approach should be adopted.


Subject(s)
Humans , Male , Graft Rejection , Graft Survival , HLA Antigens , Isoantibodies , Lung Transplantation/adverse effects
7.
Chinese Medical Journal ; (24): 172-180, 2021.
Article in English | WPRIM | ID: wpr-921256

ABSTRACT

BACKGROUND@#Acute kidney injury (AKI) is a common and serious complication following lung transplantation (LTx), and it is associated with high mortality and morbidity. This study assessed the incidence of AKI after LTx and analyzed the associated perioperative factors and clinical outcomes.@*METHODS@#This retrospective study included all adult LTx recipients at the China-Japan Friendship Hospital in Beijing between March 2017 and December 2019. The outcomes were AKI incidence, risk factors, mortality, and kidney recovery. Multivariate analysis was performed to identify independent risk factors. Survival analysis was presented using the Kaplan-Meier curves.@*RESULTS@#AKI occurred in 137 of the 191 patients (71.7%), with transient AKI in 43 (22.5%) and persistent AKI in 94 (49.2%). AKI stage 1 occurred in 27/191 (14.1%), stage 2 in 46/191 (24.1%), and stage 3 in 64/191 (33.5%) of the AKI patients. Renal replacement therapy (RRT) was administered to 35/191 (18.3%) of the patients. Male sex, older age, mechanical ventilation (MV), severe hypotension, septic shock, multiple organ dysfunction (MODS), prolonged extracorporeal membrane oxygenation (ECMO), reintubation, and nephrotoxic agents were associated with AKI (P < 0.050). Persistent AKI was independently associated with pre-operative pulmonary hypertension, severe hypotension, post-operative MODS, and nephrotoxic agents. Severe hypotension, septic shock, MODS, reintubation, prolonged MV, and ECMO during or after LTx were related to severe AKI (stage 3) (P < 0.050). Patients with persistent and severe AKI had a significantly longer duration of MV, longer duration in the intensive care unit (ICU), worse downstream kidney function, and reduced survival (P < 0.050).@*CONCLUSIONS@#AKI is common after LTx, but the pathogenic mechanism of AKI is complicated, and prerenal causes are important. Persistent and severe AKI were associated with poor short- and long-term kidney function and reduced survival in LTx patients.


Subject(s)
Aged , Humans , Male , Acute Kidney Injury/etiology , Incidence , Lung Transplantation/adverse effects , Renal Replacement Therapy , Retrospective Studies , Risk Factors
10.
J. bras. pneumol ; 46(6): e20200032, 2020. tab, graf
Article in Portuguese | LILACS | ID: biblio-1134925

ABSTRACT

RESUMO Objetivo A fibrose pulmonar familiar (FPF) é definida como uma doença pulmonar intersticial idiopática que afeta dois ou mais membros da mesma família. Nesses pacientes, os resultados têm sido insatisfatórios, apresentando alto risco de morte e disfunção crônica do enxerto pulmonar (CLAD) após o transplante de pulmão. O objetivo do presente estudo foi comparar o resultado de curto e longo prazo do transplante de pulmão em pacientes com FPF e pacientes transplantados por outras doenças pulmonares intersticiais. Métodos Foram coletados retrospectivamente dados clínicos pré e pós-transplante de 83 pacientes com fibrose pulmonar submetidos a transplante de pulmão. Os pacientes foram divididos em aqueles com fibrose pulmonar familiar (n = 9, grupo FPF) e aqueles com fibrose pulmonar não familiar (n = 74, grupo controle). Resultados O grupo FPF foi composto de quatro mulheres e cinco homens, sendo 44,5% ex-fumantes. A maioria apresentou tomografia computadorizada e evidência patológica de pneumonia intersticial usual. Os pacientes com FPF tiveram níveis significativamente menores de hemoglobina e hematócrito. Não foram observadas outras diferenças nas características pré e pós-transplante em relação ao grupo controle. A evolução clínica pós-operatória foi semelhante nos dois grupos. Não foi constatada diferença significativa na sobrevida de um ano livre de CLAD e na sobrevida em geral. Conclusão A evolução pós-transplante de pacientes com FPF foi semelhante à dos pacientes com fibrose pulmonar não familiar, embora mais pacientes com FPF tivessem anemia pré-transplante. O resultado a curto e longo prazo foi comparável em ambos os grupos. O transplante de pulmão provou ser uma opção válida para pacientes com FPF, assim como para pacientes com outros tipos de fibrose pulmonar.


ABSTRACT Objective Familial pulmonary fibrosis (FPF) is defined as an idiopathic interstitial lung disease affecting two or more members of the same family; poor outcome with high risk of death and chronic lung allograft dysfunction (CLAD) after lung transplant has been reported in these patients. The present study aimed to compare the short- and long-term outcome of lung transplants in patients with FPF and patients transplanted because of other interstitial lung diseases. Method Clinical pre- and post-transplant data from 83 consecutive patients with pulmonary fibrosis who underwent lung transplant at our centre were collected retrospectively. Patients were divided into those with familial (n=9 FPF group) and those with non-familial pulmonary fibrosis (n=74 controls). Results The FPF group was composed of 4 females and 5 males; 44.5% were ex-smokers. The majority presented their CT scan and pathology evidence of usual interstitial pneumonia. Patients with FPF had significantly lower pre-transplant levels of haemoglobin and haematocrit. No other differences in pre- and post-transplant characteristics were observed concerning controls. The clinical post-operative course was similar in the two groups. No significant difference in one-year CLAD-free survival and overall survival was observed. Conclusion The post-transplant course of patients with FPF was similar to patients with non-familial pulmonary fibrosis, although more patients with FPF had pre-transplant anaemia. Short- and long-term outcome was comparable in both groups. Lung transplant proved to be a valid option for patients with FPF as it was for patients with other types of pulmonary fibrosis.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Lung Transplantation/adverse effects , Idiopathic Pulmonary Fibrosis/surgery , Lung/diagnostic imaging , Tomography, X-Ray Computed , Retrospective Studies , Lung Diseases, Interstitial/surgery , Idiopathic Pulmonary Fibrosis/diagnosis
12.
J. bras. pneumol ; 44(2): 161-166, Mar.-Apr. 2018. tab, graf
Article in English | LILACS | ID: biblio-893910

ABSTRACT

ABSTRACT The objective of this systematic review was to select articles including chest X-ray or chest CT findings in patients who developed pulmonary tuberculosis following solid organ transplantation (lung, kidney, or liver). The following search terms were used: "tuberculosis"; "transplants"; "transplantation"; "mycobacterium"; and "lung". The databases used in this review were PubMed and the Brazilian Biblioteca Virtual em Saúde (Virtual Health Library). We selected articles in English, Portuguese, or Spanish, regardless of the year of publication, that met the selection criteria in their title, abstract, or body of text. Articles with no data on chest CT or chest X-ray findings were excluded, as were those not related to solid organ transplantation or pulmonary tuberculosis. We selected 29 articles involving a collective total of 219 patients. The largest samples were in studies conducted in Brazil and South Korea (78 and 35 patients, respectively). The imaging findings were subdivided into five common patterns. The imaging findings varied depending on the transplanted organ in these patients. In liver and lung transplant recipients, the most common pattern was the classic one for pulmonary tuberculosis (cavitation and "tree-in-bud" nodules), which is similar to the findings for pulmonary tuberculosis in the general population. The proportion of cases showing a miliary pattern and lymph node enlargement, which is most similar to the pattern seen in patients coinfected with tuberculosis and HIV, was highest among the kidney transplant recipients. Further studies evaluating clinical data, such as immunosuppression regimens, are needed in order to improve understanding of the distribution of these imaging patterns in this population.


RESUMO O objetivo desta revisão sistemática foi selecionar artigos com achados radiográficos e/ou tomográficos de tórax em pacientes que desenvolveram tuberculose pulmonar após transplante de órgãos sólidos (pulmão, rim ou fígado). Os descritores utilizados para a pesquisa foram: "tuberculosis", "transplants", "transplantation", "mycobacterium" e "lung". As bases de dados utilizadas nesta revisão foram PubMed e Biblioteca Virtual em Saúde. Foram selecionados artigos em inglês, português e espanhol, independentemente do ano de sua publicação, que possuíam em seu título, resumo ou corpo do texto os aspectos selecionados quanto ao objetivo da pesquisa. Foram excluídos artigos sem dados sobre achados de radiografia ou de TC de tórax e aqueles não relacionados com transplantes de órgão sólido ou tuberculose pulmonar. Foram selecionados 29 artigos para o estudo, somando 219 pacientes. As maiores amostras vieram de estudos realizados no Brasil e na Coreia do Sul (78 e 35 pacientes, respectivamente). Os achados de imagem foram subdivididos em cinco padrões mais comuns. Os achados de imagem nesses pacientes variaram dependendo do órgão transplantado. O padrão mais comum foi o clássico para tuberculose pulmonar (escavação e nódulos em árvore em brotamento) nos transplantados de fígado e pulmão, que é similar ao acometimento da doença na população em geral. Transplantados de rim apresentaram um maior número de casos de acometimento miliar e de linfonodomegalia, que é mais similar aos casos de pacientes coinfectados com tuberculose e HIV. Estudos que avaliem dados clínicos, como o esquema farmacológico de imunossupressão, são necessários para um melhor entendimento da distribuição desses padrões de imagem nessa população.


Subject(s)
Humans , Tuberculosis, Pulmonary/etiology , Tuberculosis, Pulmonary/diagnostic imaging , Kidney Transplantation/adverse effects , Lung Transplantation/adverse effects , Radiography, Thoracic/methods , Tomography, X-Ray Computed/methods , Incidental Findings , Immunocompetence
13.
Clinics ; 73: e166, 2018. tab, graf
Article in English | LILACS | ID: biblio-890746

ABSTRACT

OBJECTIVES: To evaluate the impact of Burkholderia cepacia complex colonization in cystic fibrosis patients undergoing lung transplantation. METHODS: We prospectively analyzed clinical data and respiratory tract samples (sputum and bronchoalveolar lavage) collected from suppurative lung disease patients between January 2008 and November 2013. We also subtyped different Burkholderia cepacia complex genotypes via DNA sequencing using primers against the recA gene in samples collected between January 2012 and November 2013. RESULTS: From 2008 to 2013, 34 lung transplants were performed on cystic fibrosis patients at our center. Burkholderia cepacia complex was detected in 13 of the 34 (38.2%) patients. Seven of the 13 (53%) strains were subjected to genotype analysis, from which three strains of B. metallica and four strains of B. cenocepacia were identified. The mortality rate was 1/13 (7.6%), and this death was not related to B. cepacia infection. CONCLUSION: The results of our study suggest that colonization by B. cepacia complex and even B. cenocepacia in patients with cystic fibrosis should not be considered an absolute contraindication to lung transplantation in Brazilian centers.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , Lung Transplantation/adverse effects , Burkholderia cepacia/isolation & purification , Burkholderia Infections/etiology , Cystic Fibrosis/microbiology , Phylogeny , Time Factors , Brazil/epidemiology , DNA, Bacterial , Prospective Studies , Regression Analysis , Risk Factors , Lung Transplantation/mortality , Treatment Outcome , Burkholderia Infections/mortality , Cystic Fibrosis/surgery , Cystic Fibrosis/complications , Cystic Fibrosis/mortality , Kaplan-Meier Estimate , Contraindications, Procedure , Intensive Care Units , Length of Stay
14.
J. bras. pneumol ; 43(4): 270-273, July-Aug. 2017. tab, graf
Article in English | LILACS | ID: biblio-893851

ABSTRACT

ABSTRACT Objective: Respiratory infections constitute a major cause of morbidity and mortality in solid organ transplant recipients. The incidence of pulmonary tuberculosis is high among such patients. On imaging, tuberculosis has various presentations. Greater understanding of those presentations could reduce the impact of the disease by facilitating early diagnosis. Therefore, we attempted to describe the HRCT patterns of pulmonary tuberculosis in lung transplant recipients. Methods: From two hospitals in southern Brazil, we collected the following data on lung transplant recipients who developed pulmonary tuberculosis: gender; age; symptoms; the lung disease that led to transplantation; HRCT pattern; distribution of findings; time from transplantation to pulmonary tuberculosis; and mortality rate. The HRCT findings were classified as miliary nodules; cavitation and centrilobular nodules with a tree-in-bud pattern; ground-glass attenuation with consolidation; mediastinal lymph node enlargement; or pleural effusion. Results: We evaluated 402 lung transplant recipients, 19 of whom developed pulmonary tuberculosis after transplantation. Among those 19 patients, the most common HRCT patterns were ground-glass attenuation with consolidation (in 42%); cavitation and centrilobular nodules with a tree-in-bud pattern (in 31.5%); and mediastinal lymph node enlargement (in 15.7%). Among the patients with cavitation and centrilobular nodules with a tree-in-bud pattern, the distribution was within the upper lobes in 66.6%. No pleural effusion was observed. Despite treatment, one-year mortality was 47.3%. Conclusions: The predominant HRCT pattern was ground-glass attenuation with consolidation, followed by cavitation and centrilobular nodules with a tree-in-bud pattern. These findings are similar to those reported for immunocompetent patients with pulmonary tuberculosis and considerably different from those reported for AIDS patients with the same disease.


RESUMO Objetivo: As infecções respiratórias constituem a principal causa de morbidade e mortalidade em transplantados de órgãos sólidos. A incidência de tuberculose pulmonar é alta entre esses pacientes. Em exames de imagem, a tuberculose tem diferentes apresentações. Uma maior compreensão dessas apresentações poderia reduzir o impacto da doença ao facilitar o diagnóstico precoce. Portanto, buscamos descrever os padrões de tuberculose pulmonar na TCAR em transplantados de pulmão. Métodos: De dois hospitais no sul do Brasil, foram coletados os seguintes dados sobre transplantados de pulmão que desenvolveram tuberculose pulmonar: sexo; idade; sintomas; doença pulmonar que levou ao transplante; padrão na TCAR; distribuição dos achados; tempo entre transplante e tuberculose pulmonar; e taxa de mortalidade. Os achados na TCAR foram classificados como nódulos miliares; cavitação e nódulos centrolobulares com padrão de árvore em brotamento; atenuação em vidro fosco com consolidação; linfonodomegalia mediastinal; ou derrame pleural. Resultados: Foram avaliados 402 transplantados de pulmão, dos quais 19 desenvolveram tuberculose pulmonar após o transplante. Entre esses 19 pacientes, os padrões mais comuns na TCAR foram atenuação em vidro fosco com consolidação (em 42%); cavitação e nódulos centrolobulares com padrão de árvore em brotamento (em 31,5%); e linfonodomegalia mediastinal (em 15,7%). Entre os pacientes com cavitação e nódulos centrolobulares com padrão de árvore em brotamento, esses achados se distribuíam nos lobos superiores em 66,6%. Não se observou derrame pleural. Apesar do tratamento, a mortalidade em um ano foi de 47,3%. Conclusões: O padrão predominante na TCAR foi atenuação em vidro fosco com consolidação, seguido por cavitação e nódulos centrolobulares com padrão de árvore em brotamento. Esses achados são semelhantes aos relatados para pacientes imunocompetentes com tuberculose pulmonar e consideravelmente diferentes dos relatados para portadores de AIDS com a mesma doença.


Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Aged , Young Adult , Tuberculosis, Pulmonary/diagnostic imaging , Lung Transplantation/adverse effects , Tuberculosis, Pulmonary/etiology , Tomography, X-Ray Computed/methods , Transplant Recipients/statistics & numerical data
15.
Rev. Soc. Bras. Med. Trop ; 49(4): 523-526, July-Aug. 2016. graf
Article in English | LILACS | ID: lil-792795

ABSTRACT

Abstract: We report herein a case of thoracic infection due to Nocardia nova following lung re-transplantation performed for emphysema related to alpha-1-antitrypsin deficiency. The infection extended from the lung into the pleural space, thoracic wall, and mediastinum, presenting as pericarditis and empyema necessitatis. Nocardia nova was identified by 16S ribosomal deoxyribonucleic acid (rDNA) sequencing and phylogenetic analysis. According to a literature search of PubMed, LILACS and MEDLINE databases, we describe herein the first case of empyema necessitatis caused by N. nova species in a transplanted patient.


Subject(s)
Humans , Female , Lung Transplantation/adverse effects , Empyema/diagnosis , Empyema/microbiology , Nocardia/genetics , Nocardia Infections/diagnosis , Reoperation , Middle Aged
16.
Neumol. pediátr. (En línea) ; 11(1): 33-37, ene. 2016. tab, graf
Article in Spanish | LILACS | ID: lil-789395

ABSTRACT

Respiratory failure is the leading cause of morbidity and mortality in patients with cystic fibrosis. Lung transplantation (LT) is the choice for those with advanced respiratory failure. LT improves the quality of life and survival of these patients. Pretransplant colonization by resistant germs such as Pseudomona aeruginosa and Methicillin-resistant Staphylococcus aureus (MRSA), are not a contraindication to transplantation. Patients infected with Burkholderia cepacia complex (Bcc) and especially those colonized with Burkhorderia cenocepacia have higher mortality after transplantation and are considered an absolute contraindication to transplantation in most centers in the world. The causes of death after transplant are surgical complications, primary graft dysfunction and infections in the first month, and chronic rejection and infection not associated with CMV after the first year. An early referral and multidisciplinary management in the pre andpost transplantation including rehabilitation, physiotherapy, and nutritional management are essential to achieve successful transplantation outcomes.


La falla respiratoria es la principal causa de morbimortalidad en pacientes con Fibrosis Quística. El trasplante pulmonar (TP) es la opción para aquellos con falla respiratoria avanzada. El TP mejora la calidad de vida y la sobrevida de estos pacientes. La colonización pretrasplante por gérmenes resistentes como Pseudomona Aureginosa y Staphylococcus aureus meticilino resistente (SAMR), no son contraindicación para trasplante. Pacientes infectados por el complejoBurkholderia cepacia (Bcc) especialmente aquellos colonizados con Burkholderia cenocepacia tienen mayor mortalidad post trasplante y es considerada una contraindicación absoluta para trasplante en la mayoría de los centros en el mundo. Las causas de muerte en el primer mes post trasplante son las complicaciones quirúrgicas, disfunción primaria de injerto e infecciones, después del primer año son rechazo crónico e infecciones no asociadas a CMV. Una derivación precoz y un manejo multidisciplinario en el pre y post trasplante que incluya rehabilitación, kinesioterapia, manejo nutricional son esenciales para el éxito del trasplante.


Subject(s)
Humans , Male , Female , Child , Cystic Fibrosis/surgery , Lung Transplantation/adverse effects , Lung Transplantation/methods , Quality of Life , Survival Rate , Survival
17.
Rev. bras. epidemiol ; 18(2): 413-424, Apr.-Jun. 2015. tab
Article in English | LILACS | ID: lil-755179

ABSTRACT

OBJECTIVE:

To evaluate the access to drugs for hypertension and diabetes and the direct cost of buying them among users of the Family Health Strategy (FHS) in the state of Pernambuco, Brazil.

METHODS:

Population-based, cross-sectional study of a systematic random sample of 785 patients with hypertension and 823 patients with diabetes mellitus who were registered in 208 randomly selected FHS teams in 35 municipalities of the state of Pernambuco. The selected municipalities were classified into three levels with probability proportional to municipality size (LS, large-sized; MS, medium-sized; SS, small-sized). To verify differences between the cities, we used the χ2 test.

RESULTS:

Pharmacological treatment was used by 91.2% patients with hypertension whereas 85.6% patients with diabetes mellitus used oral antidiabetic drugs (OADs), and 15.4% used insulin. The FHS team itself provided antihypertensive medications to 69.0% patients with hypertension, OADs to 75.0% patients with diabetes mellitus, and insulin treatment to 65.4%. The 36.9% patients with hypertension and 29.8% with diabetes mellitus that had to buy all or part of their medications reported median monthly cost of R$ 18.30, R$ 14.00, and R$ 27.61 for antihypertensive drugs, OADs, and insulin, respectively.

CONCLUSION:

It is necessary to increase efforts to ensure access to these drugs in the primary health care network.

.

OBJETIVO:

Avaliar o acesso a medicamentos para hipertensão e diabetes e o gasto direto relacionado à aquisição destes insumos entre os usuários da Estratégia Saúde da Família (ESF), no estado de Pernambuco.

MÉTODOS:

Estudo transversal, de base populacional, numa amostra aleatória sistemática de 785 pacientes hipertensos e 823 diabéticos cadastrados em 208 equipes da ESF sorteadas em 35 municípios do estado de Pernambuco. Os municípios selecionados foram classificados em três estratos com probabilidade proporcional ao tamanho do município (GP: grande porte; MP: médio porte; PP: pequeno porte). A fim de verificar diferenças entre os municípios, foi utilizado o teste χ2.

RESULTADOS:

Dos 785 hipertensos, 91,2% referiram o uso de anti-hipertensivos e dos 823 diabéticos, 85,6% utilizavam antidiabéticos orais (ADO), e 15,4%, insulina. Os anti-hipertensivos eram fornecidos pelas equipes da ESF para 69,0% dos hipertensos, os ADO, para 75,0% dos diabéticos, e a insulina e insumos, para 65,4%. Os hipertensos (36,9%) e os diabéticos (29,8%) que precisavam comprar os medicamentos referiram um gasto mediano mensal de R$ 18,30, R$ 14,00 e R$ 27,61 para anti-hipertensivos, ADO e insulina, respectivamente.

CONCLUSÃO:

É necessário ampliar os esforços para assegurar o acesso aos medicamentos na rede de atenção primária de saúde.

.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Lung Diseases/surgery , Lung Transplantation , Age Factors , Bronchiectasis/mortality , Bronchiectasis/surgery , Iran , Kaplan-Meier Estimate , Lung Diseases/mortality , Lung Transplantation/adverse effects , Lung Transplantation/mortality , Multivariate Analysis , Pulmonary Fibrosis/mortality , Pulmonary Fibrosis/surgery , Retrospective Studies , Risk Factors , Sex Factors , Time Factors , Tissue Donors , Treatment Outcome
18.
Rev. Méd. Clín. Condes ; 26(3): 367-375, mayo 2015. tab, graf
Article in Spanish | LILACS | ID: biblio-1129134

ABSTRACT

El trasplante pulmonar es considerado en la actualidad el tratamiento de elección para pacientes portadores de una patología pulmonar avanzada, sin compromiso de otro órgano vital y que tengan sobrevida esperada de menos de dos años. Ha presentado una evolución notable en los últimos años mejorando la sobrevida y calidad de vida de los pacientes, lo que ha sido asociado a la mejoría de drogas inmunosupresoras, mejor diagnóstico de situación inmunológica, técnicas de preservación del injerto, protocolos efectivos de profilaxis infecciosa y diagnóstico precoz de las complicaciones. Los desafíos en la actualidad son el déficit de órganos, que lleva aumento de lista de espera por lo que se han desarrollado técnicas de optimización de injertos, la extensión de la edad de los candidatos a trasplante y se mantiene sin grandes modificaciones la disfunción crónica de injerto.


Lung transplantation is currently considered the treatment of choice for patients with advanced lung disease, without involvement of other vital organ and have expected survival of less than two years. In recent years has presented a remarkable development improving survival and quality of life of patients, which has been associated with improvement of immunosuppressive drugs, better diagnosis of immunological state, techniques graft preservation, effective prophylaxis infectious protocols and early diagnosis of medical complications. The challenges today are the shortage of organs, which has increased waiting list so that optimization techniques have been developed graft, the extension of the age of transplant candidates and remains largely unchanged chronic dysfunction graft.


Subject(s)
Humans , Lung Transplantation/methods , Lung Transplantation/trends , Quality of Life , Survival Rate , Cause of Death , Immunosuppression Therapy , Lung Transplantation/adverse effects , Patient Selection , Antibiotic Prophylaxis , Donor Selection , Graft Rejection
19.
The Korean Journal of Internal Medicine ; : 506-514, 2015.
Article in English | WPRIM | ID: wpr-58265

ABSTRACT

BACKGROUND/AIMS: Infections are major causes of both early and late death after lung transplantation (LT). The development of prophylaxis strategies has altered the epidemiology of post-LT infections; however, recent epidemiological data are limited. We evaluated infections after LT at our institution by time of occurrence, site of infections, and microbiologic etiologies. METHODS: All consecutive patients undergoing lung or heart-lung transplantation between October 2008 and August 2014 at our institution were enrolled. Cases of infections after LT were initially identified from the prospective registry database, which was followed by a detailed review of the patients' medical records. RESULTS: A total of 108 episodes of post-LT infections (56 bacterial, 43 viral, and nine fungal infections) were observed in 34 LT recipients. Within 1 month after LT, the most common bacterial infections were catheter-related bloodstream infections (42%). Pneumonia was the most common site of bacterial infection in the 2- to 6-month period (28%) and after 6 months (47%). Cytomegalovirus was the most common viral infection within 1 month (75%) and in the 2- to 6-month period (80%). Respiratory viruses were the most common viruses after 6 months (48%). Catheter-related candidemia was the most common fungal infection. Invasive pulmonary aspergillosis developed after 6 months. Survival rates at the first and third years were 79% and 73%, respectively. CONCLUSIONS: Although this study was performed in a single center, we provide valuable and recent detailed epidemiology data for post-LT infections. A further multicenter study is required to properly evaluate the epidemiology of post-LT infections in Korea.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Bacterial Infections/diagnosis , Catheter-Related Infections/microbiology , Cytomegalovirus Infections/virology , Heart-Lung Transplantation/adverse effects , Kaplan-Meier Estimate , Lung Transplantation/adverse effects , Medical Records , Mycoses/diagnosis , Pneumonia, Bacterial/microbiology , Registries , Republic of Korea/epidemiology , Risk Factors , Time Factors , Treatment Outcome , Virus Diseases/diagnosis
20.
In. Soeiro, Alexandre de Matos; Leal, Tatiana de Carvalho Andreucci Torres; Oliveira Junior, Múcio Tavares de; Kalil Filho, Roberto. Manual de condutas práticas da unidade de emergência do InCor / Manual of Clinical management of the emergency unit of InCor. São Paulo, Manole, 1; 2015. p.992-998.
Monography in Portuguese | LILACS | ID: lil-736718
SELECTION OF CITATIONS
SEARCH DETAIL